Renascor signs Indigenous Land Use Agreement for Siviour Graphite Project

Renascor Resources (ASX:RNU) has finalised an Indigenous Land Use Agreement (ILUA) with the Barngarla Determination Aboriginal Corporation RNTBC (BDAC).

Market Update: ASX in turmoil as Israel strikes back at Iran

Brent Crude prices have surged 4.25% following Israel’s attack on Iran with the ASX200 falling 1.7% on news of the ongoing conflict in the Middle East.The price shot up from US$87 a barrel to $90.6 barrel in the space of two hours on Friday, after a decline to below US$90 mark mid...

Brent Crude and gold surge as Israel attacks Iran

Brent Crude prices surged 4.25% on Friday morning WST following reports Israel has attacked Iran in the last several hours.

Are there gains to be made with the grocery giants?

There is a growing storm of controversy around Coles (ASX:COL) and Woolworths (ASX:WOW) as they face intense scrutiny over price hikes and supplier pressures in a Senate inquiry. This raises an interesting question as to whether investors should cut ties with these corporate giants or wheth...

Sayona sells $13.7M Troilus stake to grow lithium plays as prices low

Hotly watched ASX stock Sayona Mining has sold $12M worth of shares of Toronto-listed Troilus Gold Corp to advance two key lithium assets.

Godolphin snaps up REE-prospective Narraburra in NSW

Critical and green metals- focused microcap Godolphin Resources Ltd (ASX: GRL) has taken complete control of the Narraburra rare earths project in New South Wales, acquiring the remaining 49 percent from joint venture partner EX9 Pty Ltd.According to the terms of the deal, Godolphin will pay $150...

Historical grades above 56g/t excite Metalicity ahead of gold drilling

Metalicity Ltd (ASX: MCT) is preparing to kick off drilling at West Australian gold play Yundamindra – the first activity in ten years.

Inoviq closes the gap on blood test results for ovarian cancer

INOVIQ has announced encouraging blood test identification results for ovarian cancer – cancer-positive tests saw a 76% success rate.

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to Phase III of its osteoarthritis 'program.'